Close
Back to SBTX Stock Lookup

(SBTX) – Business Wire

Oct 21, 2022 07:31 AM Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxi
Jul 21, 2022 04:00 PM Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
May 17, 2022 04:05 PM Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
May 12, 2022 04:01 PM Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Mar 31, 2022 04:00 PM Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 24, 2022 04:30 PM Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
Feb 3, 2022 04:05 PM Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Jan 5, 2022 09:00 AM Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference
Nov 12, 2021 08:30 AM Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Nov 12, 2021 08:30 AM Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
Nov 11, 2021 04:05 PM Silverback Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
Nov 10, 2021 04:05 PM Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Oct 5, 2021 08:00 AM Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
Sep 16, 2021 03:30 AM Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressin
Sep 13, 2021 08:00 AM Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
Sep 7, 2021 04:25 PM Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 12, 2021 04:05 PM Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 3, 2021 08:00 AM Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Jul 7, 2021 07:30 AM Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric
Jun 15, 2021 08:00 AM Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
Jun 1, 2021 07:59 AM Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
May 13, 2021 04:05 PM Silverback Therapeutics Reports First Quarter 2021 Financial Results
Apr 8, 2021 08:00 AM Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
Mar 29, 2021 04:05 PM Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates
Mar 15, 2021 08:00 AM Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors
Feb 16, 2021 08:00 AM Silverback Therapeutics to Present at Upcoming Investor Conferences
Dec 8, 2020 05:00 PM Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dec 3, 2020 10:44 PM Silverback Therapeutics Announces Pricing of Initial Public Offering

Back to SBTX Stock Lookup